EXELIXIS INC (EXEL)
US30161Q1040 - Common Stock
Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
/PRNewswire/ -- Sairopa B.V., today announced it has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis, Inc....
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
2 Biotech Stocks to Buy Hand Over Fist in December
2 Biotech Stocks to Buy Hand Over Fist in December
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects.
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks.
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
EXEL earnings call for the period ending September 30, 2024.
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
1 No-Brainer Stock to Buy With $40
The midcap biotech just became an even better buy.
First Week of December 20th Options Trading For Exelixis (EXEL)
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Noteworthy Tuesday Option Activity: KSS, EXEL, IBKR
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
Exelixis Moves Up In Market Cap Rank, Passing Bath & Body Works
2 Growth Stocks to Buy With Less Than $100
No need to break the bank to get in on these likely long-term winners.